NCT05456243 Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients
| NCT ID | NCT05456243 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Mayo Clinic |
| Condition | Kidney Transplant |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2023-01-30 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 12 participants in total. It began in 2023-01-30 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research study is being done to learn if an experimental treatment of infusing allogeneic adipose-derived mesenchymal stromal cells (allo-A-MSC ) directly into the renal artery is safe and can help reduce inflammation in the transplanted kidney and treat rejection.
Eligibility Criteria
Inclusion Criteria: * Able to understand and provide informed consent. * Have received a renal transplant (first or repeat), and the most recent protocol biopsy within 3 months of consent is diagnostic for ABMR or cellular rejection. Clinical Inclusion Criteria: * Stable renal function: * Serum creatinine at the time of surveillance biopsy cannot be \> 15% greater than the serum creatine prior to the biopsy (must be within 3 months of the biopsy); * Estimated eGFR \> 30 ml/min by MDRD. Histologic Criteria for Eligibility: * ABMR: microvascular inflammation scores for glomerulitis (g) and peritubular capillaritis (ptc) (g:1 or 2; ptc:1 or 2). * Cellular rejection: tubulitis (t) (t:1or 2); interstitial inflammation (i) (i:1 or 2); intimal arteritis (v) (v: 1 or 2). * Mixed ABMR and cellular rejection. Exclusion Criteria: * Nephrotic range proteinuria (≥ 3.5g/24h), detected more than once in the year preceding screening. * History of post-transplant intervention for obstructive uropathy * One or more of the following laboratory values: o Hemoglobin (Hb} ≤ 8 g/dL, Potassium (K) ≥ 5.5 mEq/dL, Alanine aminotransferase (ALT) ≥ 60 U/L, Hemoglobin A1C (HbA1c) ≥ 7%, International Normalized Ratio (INR) ≥ 2.0, Platelet count \< 50 x 109/L (patients who receive a platelet transfusion to increase their platelet count will not be excluded). * One or more of the following parameters: o Temperature ≥ 38°C (100.4°F), Respiratory rate ≥ 20/min, Oxygen saturation (SpO2) ≤ 90%, Systemic systolic blood pressure \>160mmHg or \< 100 mmHg, Pulse \< 45/min or \> 140/min * Patients with the following grades/classes of vascular diseases: * NYHA Class 3-4 CHF * Uncontrolled arrhythmia, defined as: atrial fibrillation with rapid ventricular response, supraventricular tachycardia, Wolff-Parkinson-White syndrome, ventricular fibrillation, or sick sinus syndrome. Subjects with rate-controlled chronic atrial fibrillation will be allowed to participate. * Cerebrovascular accident (CVA) within 90 days of screening * Peripheral Arterial Disease (PAD), patients who have had prior vascular interventions for PAD in the index lower extremity. * Acute illness within 30 days of screening. * History of allergy or intolerance to iodinated contrast agents * Women of childbearing potential or male subjects with female partners of childbearing potential unwilling to use an effective method of contraception during and for 12 months post-treatment. * History of or current evidence of alcohol abuse, illicit drug use or dependence * Active COVID 19 or positive test for the SARS-CoV-2 virus * History of malignancy within 5 years of enrollment. History of adequately treated in-situ cervical carcinoma and/or adequately treated skin cancer (basal or squamous cell) will be permitted * Serologic evidence of human immunodeficiency virus 1 or 2 infection * Epstein Barr Virus (EBV) sero-negativity (EBV naïve) * Cytomegalovirus (CMV) sero-negativity * Active post-transplant opportunistic infections at the time of screening (CMV, BK virus, polyoma virus, EBV) * Active Hepatitis B or Hepatitis C infection (e.g. NAT positive), and/or HBV core antibody positivity. Subjects with previously treated Hepatitis C (NAT negative, HCV IgG positive), or those with HBV surface antibody positive but HBV core antibody negative subjects will not be excluded from the study. * Have received a kidney transplant from a Hepatitis C positive donor and plan to receive anti-viral treatment after transplant * Any chronic condition for which anti-coagulation cannot be safely interrupted for kidney biopsy based on the CHA2DS2-VASc score of ≥ 6 risk stratum. If subjects fall into either the high or the moderate thrombotic risk, they will be deemed to be not safe to interrupt anticoagulation: * High thrombotic risk: Mechanical heart valve: Any mitral valve prosthesis, any caged-ball or tilting disc aortic valve prosthesis, recent (within 6 months) stroke or transient ischemic attack; Atrial Fibrillation: CHADS2 score 5-6, CHA2DS2-VASc score 7-9, recent (within 3 months) stroke or transient ischemic attack, rheumatic valvular heart disease; Venous thromboembolism: Recent (within 3 months) VTE, severe thrombophilia (e.g. deficiency of protein C, protein S, or antithrombin; antiphospholipid antibodies; multiple abnormalities) * Moderate thrombotic risk: Mechanical heart valve: Bileaflet aortic valve prosthesis and 1 or more of the of following risk factors: atrial fibrillation, prior stroke or transient ischemic attack, hypertension, diabetes, congestive heart failure; Atrial Fibrillation: CHADS2 score 3-4, CHA2DS2-VASc score 4-6; Venous thromboembolism: VTE within the past 3 to 12 months, non-severe thrombophilia (e.g. heterozygous factor V Leiden or prothrombin gene mutation), recurrent VTE * For all other subjects, anticoagulation can be safely interrupted for 3 days prior to infusion and resumed a day after the infusion. * Positive pregnancy test * Participation in any other studies that involved investigational drugs or regimens in the preceding year * Any other condition, in the investigator's judgment, that increases the risk of A-MSC infusion or prevents safe trial participation * Unwilling or unable to adhere to study requirements and procedures * Per Banff criteria category 6: the presence of other changes not considered to be caused by acute or chronic rejection, BK-Virus Nephropathy, Posttransplant Lymphoproliferative Disorder, Calcineurin Inhibitor Toxicity, Acute Tubular Injury, Recurrent Disease, De Novo Glomerulopathy (Other Than TG), Pyelonephritis or Drug-Induced Interstitial Nephritis
Contact & Investigator
Timucin Taner, MD, PhD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT05456243 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Kidney Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05456243 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05456243 currently recruiting?
Yes, NCT05456243 is actively recruiting participants. Visit ClinicalTrials.gov or contact Mayo Clinic to inquire about joining.
Where is the NCT05456243 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT05456243 clinical trial?
NCT05456243 is sponsored by Mayo Clinic. The principal investigator is Timucin Taner, MD, PhD at Mayo Clinic. The trial plans to enroll 12 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.